REFERENCES
2. Shern JF, Selfe J, Izquierdo E, et al. Genomic classification and clinical outcome in rhabdomyosarcoma: a report from an International Consortium. J Clin Oncol. 2021;39:2859-71.
3. Chen X, Stewart E, Shelat AA, et al.; St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell. 2013;24:710-24.
4. Martin-Giacalone BA, Weinstein PA, Plon SE, Lupo PJ. Pediatric rhabdomyosarcoma: epidemiology and genetic susceptibility. J Clin Med. 2021;10:2028.
5. Sankhe CS, Hall L, Kendall GC. Fusion oncogenes in rhabdomyosarcoma: model systems, mechanisms of tumorigenesis, and therapeutic implications. Front Oncol. 2025;15:1570070.
6. Marshall AD, Grosveld GC. Alveolar rhabdomyosarcoma - the molecular drivers of PAX3/7-FOXO1-induced tumorigenesis. Skelet Muscle. 2012;2:25.
7. Turco GM, Oberoi S, Ladle B, et al. Towards directed therapy for fusion-positive rhabdomyosarcoma. Pharmacol Ther. 2025;276:108931.
8. Miwa S, Yamamoto N, Hayashi K, Takeuchi A, Igarashi K, Tsuchiya H. Recent advances and challenges in the treatment of rhabdomyosarcoma. Cancers. 2020;12:1758.
9. Martino E, Casamassima G, Castiglione S, et al. Vinca alkaloids and analogues as anti-cancer agents: looking back, peering ahead. Bioorg Med Chem Lett. 2018;28:2816-26.
10. Willits I, Price L, Parry A, et al. Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005;92:1626-35.
11. Bergeron C, Jenney M, De Corti F, et al.; European paediatric Soft tissue sarcoma Study Group (EpSSG). Embryonal rhabdomyosarcoma completely resected at diagnosis: the European paediatric Soft tissue sarcoma Study Group RMS2005 experience. Eur J Cancer. 2021;146:21-9.
12. Zarrabi A, Perrin D, Kavoosi M, et al. Rhabdomyosarcoma: current therapy, challenges, and future approaches to treatment strategies. Cancers. 2023;15:5269.
13. Vaidya FU, Sufiyan Chhipa A, Mishra V, et al. Molecular and cellular paradigms of multidrug resistance in cancer. Cancer Rep. 2022;5:e1291.
14. Muñoz-Maldonado C, Zimmer Y, Medová M. A comparative analysis of individual RAS mutations in cancer biology. Front Oncol. 2019;9:1088.
15. Danielli SG, Porpiglia E, De Micheli AJ, et al. Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance. Sci Adv. 2023;9:eade9238.
17. Odeniyide P, Yohe ME, Pollard K, et al. Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma. Oncogene. 2022;41:3037.
18. Garcia N, Del Pozo V, Yohe ME, et al. Vertical inhibition of the RAF-MEK-ERK cascade induces myogenic differentiation, apoptosis, and tumor regression in H/NRASQ61X mutant rhabdomyosarcoma. Mol Cancer Ther. 2022;21:170-83.
19. Kim A, Widemann BC, Krailo M, et al. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2015;62:1562-6.
20. Yohe ME, Gryder BE, Shern JF, et al. MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma. Sci Transl Med. 2018;10:eaan4470.
21. Hebron KE, Wan X, Roth JS, et al. The combination of Trametinib and Ganitumab is effective in RAS-mutated PAX-fusion negative rhabdomyosarcoma models. Clin Cancer Res. 2023;29:472-87.
22. Dolgikh N, Hugle M, Vogler M, Fulda S. NRAS-mutated rhabdomyosarcoma cells are vulnerable to mitochondrial apoptosis induced by coinhibition of MEK and PI3Kα. Cancer Res. 2018;78:2000-13.
23. Stewart E, McEvoy J, Wang H, et al.; St. Jude Children’s Research Hospital - Washington University Pediatric Cancer Genome Project. Identification of therapeutic targets in rhabdomyosarcoma through integrated genomic, epigenomic, and proteomic analyses. Cancer Cell. 2018;34:411-26.e19.
24. Slemmons KK, Crose LE, Rudzinski E, Bentley RC, Linardic CM. Role of the YAP oncoprotein in priming Ras-driven rhabdomyosarcoma. PLoS One. 2015;10:e0140781.
25. Marampon F, Gravina GL, Di Rocco A, et al. MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals. Mol Cancer Ther. 2011;10:159-68.
26. Winkler M, Friedrich J, Boedicker C, Dolgikh N. Co-targeting MCL-1 and ERK1/2 kinase induces mitochondrial apoptosis in rhabdomyosarcoma cells. Transl Oncol. 2022;16:101313.
27. Vo KT, Sabnis AJ, Williams PM, et al. Phase II study of Ulixertinib in children and young adults with tumors harboring activating mitogen-activated protein kinase pathway alterations: APEC1621J of the National Cancer Institute-Children’s Oncology Group pediatric MATCH trial. JCO Precis Oncol. 2024;8:e2400103.
28. Tenente IM, Hayes MN, Ignatius MS, et al. Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma. Elife. 2017;6:e19214.
29. Pomella S, Cassandri M, D’Archivio L, et al. MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting. Nat Commun. 2023;14:8373.
30. Di Rocco A, Camero S, Benedetti A, et al. Anti-oncogenic and pro-myogenic action of the MKK6/p38/AKT axis induced by targeting MEK/ERK in embryonal rhabdomyosarcoma. Oncol Rep. 2022;48:151.
31. Ramadan F, Fahs A, Ghayad SE, Saab R. Signaling pathways in rhabdomyosarcoma invasion and metastasis. Cancer Metastasis Rev. 2020;39:287-301.
32. Piazzi M, Bavelloni A, Cenni V, et al. Combined treatment with PI3K inhibitors BYL-719 and CAL-101 is a promising antiproliferative strategy in human rhabdomyosarcoma cells. Molecules. 2022;27:2742.
33. Vanhaesebroeck B, Perry MWD, Brown JR, André F, Okkenhaug K. PI3K inhibitors are finally coming of age. Nat Rev Drug Discov. 2021;20:741-69.
34. Codenotti S, Zizioli D, Mignani L, et al. Hyperactive Akt1 signaling increases tumor progression and DNA repair in embryonal rhabdomyosarcoma RD line and confers susceptibility to glycolysis and mevalonate pathway inhibitors. Cells. 2022;11:2859.
35. Kilic-Eren M, Boylu T, Tabor V. Targeting PI3K/Akt represses Hypoxia inducible factor-1α activation and sensitizes rhabdomyosarcoma and Ewing’s sarcoma cells for apoptosis. Cancer Cell Int. 2013;13:36.
36. Gallo-Oller G, Pons G, Sansa-Girona J, et al. TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma. Exp Hematol Oncol. 2024;13:38.
37. Renshaw J, Taylor KR, Bishop R, et al. Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. Clin Cancer Res. 2013;19:5940-51.
38. Guenther MK, Graab U, Fulda S. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma. Cancer Lett. 2013;337:200-9.
39. Fiorito E, Szybowska P, Haugsten EM, et al. Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma. Br J Cancer. 2022;127:1939-53.
40. Cen L, Hsieh FC, Lin HJ, Chen CS, Qualman SJ, Lin J. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound. Br J Cancer. 2007;97:785-91.
41. Manzella G, Schreck LD, Breunis WB, et al. Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity. Nat Commun. 2020;11:4629.
42. Preuss E, Hugle M, Reimann R, Schlecht M, Fulda S. Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein. J Biol Chem. 2013;288:35287-96.
43. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;169:361-71.
44. Felkai L, Krencz I, Kiss DJ, et al. Characterization of mTOR activity and metabolic profile in pediatric rhabdomyosarcoma. Cancers. 2020;12:1947.
45. Anderson JL, Park A, Akiyama R, Tap WD, Denny CT, Federman N. Evaluation of in vitro activity of the class I PI3K inhibitor buparlisib (BKM120) in pediatric bone and soft tissue sarcomas. PLoS One. 2015;10:e0133610.
46. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007;26:1932-40.
47. Abraham J, Prajapati SI, Nishijo K, et al. Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. Mol Cancer Ther. 2011;10:697-707.
48. De Giovanni C, Landuzzi L, Palladini A, Nicoletti G, Nanni P, Lollini PL. HER tyrosine kinase family and rhabdomyosarcoma: role in onset and targeted therapy. Cells. 2021;10:1808.
49. Marampon F, Di Nisio V, Pietrantoni I, et al. Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines. Cancer Lett. 2019;461:90-101.
50. Codenotti S, Sandrini L, Mandracchia D, et al. Statin-sensitive Akt1/Src/Caveolin-1 signaling enhances oxidative stress resistance in rhabdomyosarcoma. Cancers. 2024;16:853.
51. Codenotti S, Asperti M, Poli M, et al. Synthetic inhibition of SREBP2 and the mevalonate pathway blocks rhabdomyosarcoma tumor growth in vitro and in vivo and promotes chemosensitization. Mol Metab. 2025;92:102085.
52. Cao Z, Liao Q, Su M, Huang K, Jin J, Cao D. AKT and ERK dual inhibitors: the way forward? Cancer Lett. 2019;459:30-40.
53. Shimizu T, Tolcher AW, Papadopoulos KP, et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res. 2012;18:2316-25.
54. Ghomlaghi M, Hart A, Hoang N, Shin S, Nguyen LK. Feedback, crosstalk and competition: ingredients for emergent non-linear behaviour in the PI3K/mTOR signalling network. Int J Mol Sci. 2021;22:6944.
55. Godwin P, Baird AM, Heavey S, Barr MP, O’Byrne KJ, Gately K. Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol. 2013;3:120.
56. Tago K, Funakoshi-Tago M, Ohta S, et al. Oncogenic Ras mutant causes the hyperactivation of NF-κB via acceleration of its transcriptional activation. Mol Oncol. 2019;13:2493-510.
57. Londhe P, Yu PY, Ijiri Y, et al. Classical NF-κB metabolically reprograms sarcoma cells through regulation of hexokinase 2. Front Oncol. 2018;8:104.
58. Salucci S, Bavelloni A, Stella AB, et al. The cytotoxic effect of curcumin in rhabdomyosarcoma is associated with the modulation of AMPK, AKT/mTOR, STAT, and p53 signaling. Nutrients. 2023;15:740.
59. Cleary MM, Mansoor A, Settelmeyer T, et al. NFκB signaling in alveolar rhabdomyosarcoma. Dis Model Mech. 2017;10:1109-15.
60. Crose LEC, Galindo KA, Kephart JG, et al. Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression. J Clin Invest. 2014;124:285-96.
61. Mohamed A, Sun C, De Mello V, et al. The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma. J Pathol. 2016;240:3-14.
62. Adams JM, Cory S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 2018;25:27-36.
63. Armistead PM, Salganick J, Roh JS, et al. Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients. Cancer. 2007;110:2293-303.
64. Montero J, Letai A. Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Differ. 2018;25:56-64.
65. Meister MT, Boedicker C, Klingebiel T, Fulda S. Hedgehog signaling negatively co-regulates BH3-only protein Noxa and TAp73 in TP53-mutated cells. Cancer Lett. 2018;429:19-28.
66. Faqar-Uz-Zaman SF, Heinicke U, Meister MT, Vogler M, Fulda S. BCL-xL-selective BH3 mimetic sensitizes rhabdomyosarcoma cells to chemotherapeutics by activation of the mitochondrial pathway of apoptosis. Cancer Lett. 2018;412:131-42.
67. Heinicke U, Haydn T, Kehr S, Vogler M, Fulda S. BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis. Oncogene. 2018;37:5325-39.
68. Alcon C, Manzano-Muñoz A, Prada E, et al. Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance. Cell Death Dis. 2020;11:634.
69. Alcon C, Martín F, Prada E, et al. MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment. Cell Death Discov. 2022;8:172.
70. Emran TB, Shahriar A, Mahmud AR, et al. Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches. Front Oncol. 2022;12:891652.
71. Wertz IE, Kusam S, Lam C, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 2011;471:110-4.
72. Shern JF, Chen L, Chmielecki J, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014;4:216-31.
73. Toulany M, Lee KJ, Fattah KR, et al. Akt promotes post-irradiation survival of human tumor cells through initiation, progression, and termination of DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Res. 2012;10:945-57.
74. Liu L, Dai X, Yin S, et al. DNA-PK promotes activation of the survival kinase AKT in response to DNA damage through an mTORC2-ECT2 pathway. Sci Signal. 2022;15:eabh2290.
75. Shin S, Walker KA, Yoon SO. The PIKK-AKT connection in the DNA damage response. Sci Signal. 2022;15:eabm6211.
76. Fok JHL, Ramos-Montoya A, Vazquez-Chantada M, et al. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. Nat Commun. 2019;10:5065.
77. Roberts AG. The structure and mechanism of drug transporters. Methods Mol Biol. 2021;2342:193-234.
78. Fruci D, Cho WC, Nobili V, Locatelli F, Alisi A. Drug transporters and multiple drug resistance in pediatric solid tumors. Curr Drug Metab. 2016;17:308-16.
79. Xiao H, Zheng Y, Ma L, Tian L, Sun Q. Clinically-relevant ABC transporter for anti-cancer drug resistance. Front Pharmacol. 2021;12:648407.
80. Ahmed Juvale II, Abdul Hamid AA, Abd Halim KB, Che Has AT. P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease. Heliyon. 2022;8:e09777.
81. Komdeur R, Klunder J, van der Graaf WT, et al. Multidrug resistance proteins in rhabdomyosarcomas: comparison between children and adults. Cancer. 2003;97:1999-2005.
82. Seitz G, Warmann SW, Vokuhl CO, et al. Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma. Pediatr Surg Int. 2007;23:431-9.
83. Citti A, Boldrini R, Inserra A, et al. Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy. Int J Oncol. 2012;41:117-24.
84. Rashid K, Ahmad A, Liang L, Liu M, Cui Y, Liu T. Solute carriers as potential oncodrivers or suppressors: their key functions in malignant tumor formation. Drug Discov Today. 2021;26:1689-701.
85. Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol. 2012;165:1260-87.
86. Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12:599-620.
87. Codenotti S, Poli M, Asperti M, Zizioli D, Marampon F, Fanzani A. Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell lines. J Cancer Res Clin Oncol. 2018;144:1717-30.
88. Picher EA, Wahajuddin M, Barth S, Chisholm J, Shipley J, Pors K. The capacity of drug-metabolising enzymes in modulating the therapeutic efficacy of drugs to treat rhabdomyosarcoma. Cancers. 2024;16:1012.
89. Manikandan P, Nagini S. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. 2018;19:38-54.
90. Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos. 2006;34:1317-27.
91. Yao D, Ding S, Burchell B, Wolf CR, Friedberg T. Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. J Pharmacol Exp Ther. 2000;294:387-95.
92. Molina-Ortiz D, Camacho-Carranza R, González-Zamora JF, et al. Differential expression of cytochrome P450 enzymes in normal and tumor tissues from childhood rhabdomyosarcoma. PLoS One. 2014;9:e93261.
93. Molina-Ortiz D, Torres-Zárate C, Cárdenas-Cardós R, et al. Aberrant expression of CYP2W1 in pediatric soft tissue sarcomas: clinical significance and potential as a therapeutic target. Curr Oncol. 2025;32:131.
94. Hettmer S, Linardic CM, Kelsey A, et al. Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: a consensus view from European paediatric Soft tissue sarcoma Study Group, Children’s Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. Eur J Cancer. 2022;172:367-86.
95. Pacenta HL, Allen-Rhoades W, Langenau D, et al. Prioritization of novel agents for patients with rhabdomyosarcoma: a report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force. J Clin Med. 2021;10:1416.
96. Ghilu S, Morton CL, Vaseva AV, Zheng S, Kurmasheva RT, Houghton PJ. Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma. Cancer Drug Resist. 2022;5:80-9.
